Cargando…
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy
Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly tre...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196151/ https://www.ncbi.nlm.nih.gov/pubmed/25216514 |
_version_ | 1782339434596794368 |
---|---|
author | Aichler, Michaela Motschmann, Martin Jütting, Uta Luber, Birgit Becker, Karen Ott, Katja Lordick, Florian Langer, Rupert Feith, Marcus Siewert, Jörg Rüdiger Walch, Axel |
author_facet | Aichler, Michaela Motschmann, Martin Jütting, Uta Luber, Birgit Becker, Karen Ott, Katja Lordick, Florian Langer, Rupert Feith, Marcus Siewert, Jörg Rüdiger Walch, Axel |
author_sort | Aichler, Michaela |
collection | PubMed |
description | Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly treated EAC patients have not been identified yet. We investigated the epidermal growth factor receptor (EGFR) in prognosis and chemotherapy resistance in these patients. Two EAC patient cohorts, either treated by neoadjuvant cisplatin-based chemotherapy followed by surgery (n=86) or by surgical resection (n=46) were analyzed for EGFR protein expression and gene copy number. Data were correlated with clinical and histopathological response, disease-free and overall survival. In case of EGFR overexpression, the prognosis for neoadjuvant chemotherapy responders was poor as in non-responders. Responders had a significantly better disease-free survival than non-responders only if EGFR expression level (p=0.0152) or copy number (p=0.0050) was low. Comparing neoadjuvantly treated patients and primary resection patients, tumors of non-responder patients more frequently exhibited EGFR overexpression, providing evidence that EGFR is a factor for indicating chemotherapy resistance. EGFR overexpression and gene copy number are independent adverse prognostic factors for neoadjuvant chemotherapy-treated EAC patients, particularly for responders. Furthermore, EGFR overexpression is involved in resistance to cisplatin-based neoadjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-4196151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-41961512014-10-21 Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy Aichler, Michaela Motschmann, Martin Jütting, Uta Luber, Birgit Becker, Karen Ott, Katja Lordick, Florian Langer, Rupert Feith, Marcus Siewert, Jörg Rüdiger Walch, Axel Oncotarget Clinical Research Paper Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly treated EAC patients have not been identified yet. We investigated the epidermal growth factor receptor (EGFR) in prognosis and chemotherapy resistance in these patients. Two EAC patient cohorts, either treated by neoadjuvant cisplatin-based chemotherapy followed by surgery (n=86) or by surgical resection (n=46) were analyzed for EGFR protein expression and gene copy number. Data were correlated with clinical and histopathological response, disease-free and overall survival. In case of EGFR overexpression, the prognosis for neoadjuvant chemotherapy responders was poor as in non-responders. Responders had a significantly better disease-free survival than non-responders only if EGFR expression level (p=0.0152) or copy number (p=0.0050) was low. Comparing neoadjuvantly treated patients and primary resection patients, tumors of non-responder patients more frequently exhibited EGFR overexpression, providing evidence that EGFR is a factor for indicating chemotherapy resistance. EGFR overexpression and gene copy number are independent adverse prognostic factors for neoadjuvant chemotherapy-treated EAC patients, particularly for responders. Furthermore, EGFR overexpression is involved in resistance to cisplatin-based neoadjuvant chemotherapy. Impact Journals LLC 2014-07-26 /pmc/articles/PMC4196151/ /pubmed/25216514 Text en Copyright: © 2014 Aichler et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Aichler, Michaela Motschmann, Martin Jütting, Uta Luber, Birgit Becker, Karen Ott, Katja Lordick, Florian Langer, Rupert Feith, Marcus Siewert, Jörg Rüdiger Walch, Axel Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
title | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
title_full | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
title_fullStr | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
title_full_unstemmed | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
title_short | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
title_sort | epidermal growth factor receptor (egfr) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196151/ https://www.ncbi.nlm.nih.gov/pubmed/25216514 |
work_keys_str_mv | AT aichlermichaela epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT motschmannmartin epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT juttinguta epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT luberbirgit epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT beckerkaren epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT ottkatja epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT lordickflorian epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT langerrupert epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT feithmarcus epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT siewertjorgrudiger epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy AT walchaxel epidermalgrowthfactorreceptoregfrisanindependentadverseprognosticfactorinesophagealadenocarcinomapatientstreatedwithcisplatinbasedneoadjuvantchemotherapy |